News Immune System May Harbor Natural Way of Fighting MS, Other Autoimmune Diseases Immune System May Harbor Natural Way of Fighting MS, Other Autoimmune Diseases by Joana Fernandes, PhD | November 7, 2016 Share this article: Share article via email Copy article link A variant in theĀ TYK2Ā gene, which encodes an immune system protein, may work to protect people fromĀ autoimmune disorders, including multiple sclerosis (MS), without overly depressing the body’s ability to fight opportunistic infections, researchers at theĀ University of Oxford report. Their study, āResolving TYK2 Locus Genotype-To-Phenotype Differences In Autoimmunity,ā was published in the journal Science Translational Medicine. Autoimmune diseasesĀ are characterized by overlyĀ active cells of the immune system, which react against the body. For that reason, current treatments for MS and other autoimmuneĀ disorders include effects that weaken the immune system, but these therapies leave patients vulnerable to infections and other illnesses. To understand which molecular mechanisms could help balance immune system activity, researchers investigated genetic variants, influencing the function of a gene called TYK2. The protein produced by this gene (with the same name) plays a crucial role in maintaining a person’s immunity, as it contributes to fighting off infections or cancer. However, this protein can also promote the development of autoimmune disorders. Importantly, researchers found that a single variation in the TYK2 gene led to reduced production of the protein ā to levelsĀ thatĀ were no longer able to trigger autoimmune disorders, but were just enough to stillĀ protect a person against other diseases. These results indicate that treatments that promote optimal production levels of TYK2 may be effectiveĀ and safe options for patients with autoimmune disorders. āDeveloping new drugs is a costly and time-consuming process,ā said Lars Fugger, the study’s senior author, in a news release. āOn average it costs over Ā£1 billion and takes over 10 years to bring a new drug to market, and more than 90% of drugs that enter into clinical trials are not ultimately approved. This is because the majority of drugs fail to demonstrate sufficient efficacy to treat disease or they are associated with severe unwanted side effects.ā āWhile our research indicates that TYK2 could be a good drug target for treating autoimmune diseases, drugs that block the activity of immune cells have been known to leave patients vulnerable to infections and to increase the risk of cancer,ā he added. āHowever, by interrogating data available through the UK Biobank, the most comprehensive health study in the UK, we found that people carrying the protective TYK2 genetic variant were no more likely to have serious infections or to develop cancer than people without the variant.ā Print This Page About the Author Joana Fernandes, PhD Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology. Tags autoimmune disorders, genetic variants, immune system
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8
April 18, 2024 News by Lindsey Shapiro, PhD AAN 2024: Ocrevus benefits Black, Hispanic patients same as whites
April 17, 2024 News by Marisa Wexler, MS AAN 2024: Fertility treatment in MS doesn’t increase relapse risk